Clinical Trial Update: Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of vorinostat and bortezomib in relapsed or refractory T-cell non-Hodgkin lymphoma was terminated; results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Non-hodgkin Lymphoma

Drugs mentioned

• Velcade (bortezomib)
• Zolinza (vorinostat)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2010-07-09